DistantNews
Support us
🇮🇱 Israel /Health & Science

Israeli PolyPid signs $320 million deal to sell drug preventing surgical infections in US, Canada

From Jerusalem Post · () English

Summarized and contextualized by DistantNews.

At a glance

News Named sources New plan
  • Israeli biotech firm PolyPid has agreed to a deal with Azurity Pharmaceuticals to commercialize a drug preventing surgical site infections in the US and Canada.
  • The agreement could be worth over $320 million, including initial payments and future milestone payments based on regulatory and sales success.
  • PolyPid will retain global rights outside North America and will supply the drug to Azurity, marking a significant step in the company's transition to a commercial stage.

Israeli biotech company PolyPid announced a significant commercialization deal with Azurity Pharmaceuticals for its drug D-PLEX100, designed to prevent surgical site infections. The agreement could bring PolyPid more than $320 million in potential payments.

PolyPid will receive $15 million upon signing and another $15 million if the US Food and Drug Administration accepts its new drug application, expected next month. Further payments, potentially up to $300 million, are tied to regulatory, development, and sales milestones. Following commercialization, PolyPid will manufacture and supply D-PLEX100 to Azurity at a transfer price and will earn tiered royalties.

D-PLEX100 aims to deliver prolonged, localized antibacterial activity directly at surgical sites to prevent infections. The partners may also jointly pursue expanding the drug's use beyond abdominal infections in the US and Canada, with Azurity providing funding. PolyPid will maintain global commercial rights outside the US and Canada, along with worldwide manufacturing rights and full ownership of its PLEX platform and Kynatrix technology.

"This partnership is a defining step in PolyPid's transition into a commercial-stage company," said PolyPid CEO Dikla Czaczkes Akselbrad. The deal signifies a major milestone for the company as it moves towards broader market access for its innovative drug.

This partnership is a defining step in PolyPid's transition into a commercial-stage company.

— Dikla Czaczkes AkselbradPolyPid CEO commenting on the significance of the deal.
DistantNews Editorial

Originally published by Jerusalem Post. Summarized and contextualized by our editorial team with added local perspective. Read our editorial standards.

More Stories

From Our Blog